Dimerix Ltd., of Melbourne, Australia, added Liz Jazwinska to its board. Jazwinska has more than 25 years of experience in R&D management and drug portfolio business development. Read More
Twi Pharmaceuticals Inc., of Taipei, Taiwan, said its subsidiary, Twi Biotechnology Inc., and Castle Creek Pharmaceuticals LLC, a spin-off of Northbrook, Ill.,-based Marathon Pharmaceuticals LLC, entered a development and commercialization agreement for Twi's lead drug candidate, AC-203, in development for the treatment of epidermolysis bullosa. Read More
HONG KONG – Vaccine developers in China are stepping up their game to close China's gap with other countries in the novel vaccine development space. Read More
HONG KONG – Japanese and French researchers have discovered the cellular signaling mechanism whereby the balance of disturbed inhibitory synaptic connections is restored, which could have important implications for the management of neurological disorders such as epilepsy and possibly even autism, they reported in the Dec. 17, 2015, issue of Cell Reports. Read More
SINGAPORE – Getting East to meet West in drug approval guidelines might make more headway if regulators in Asia looked harder for adaptive licensing prospects, an idea that caught the attention of policymakers in Singapore in 2010, but has since fallen to the wayside regionally. Read More
SHANGHAI – Hutchison Medipharma Ltd., of Shanghai, one of China's biotech pioneers with a deep pipeline of small-molecule oncology and autoimmune candidates, has started dosing Chinese patients with neuroendocrine tumors (NETs) in a phase III trial of sulfatinib. Read More
HONG KONG – Fear of biosimilars, drugs that once launched will potentially capture entire markets with their discounted prices, is not likely to be an issue in some of the poorer countries in Asia and Latin America, where even cheaper biosimilars are too expensive for the general public. With numerous patient access challenges, biosimilars have had a difficult time finding their footing in some of these markets. Read More
HONG KONG – Samsung Biologics broke ground Monday on its third and largest biopharmaceutical production plant. Once completed, the company expects the KRW850 billion (US$722 million) plant in Incheon, Korea, to be the largest in the world. Read More
